Post-earnings recap
Reported
Wed, Aug 5, 2026
EPS actual
$3.02
EPS est.
$2.72
EPS surprise
+10.99%
1-day move
+11.36%
Charles River Laboratories reported stronger-than-expected earnings per share, which contributed to a significant stock increase of 11.36%. However, revenue figures were not disclosed, leaving some uncertainty about overall performance. Investors reacted positively to the EPS beat, indicating confidence in the company's profitability.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.02 | $2.74 | +10.99% |
| Revenue | — | $977M | — |
No transcript is on record, and the analysis is based solely on numerical results.
Charles River Laboratories International, Inc. (CRL) is a key player in the health care sector, specializing in life sciences tools and services. The company provides essential support for the pharmaceutical and biotechnology industries, helping them develop new drugs and therapies. As the demand for innovative health solutions continues to rise, CRL's role becomes increasingly important.
Last quarter
In Q1-2026, Charles River Laboratories reported an EPS of $2.06, exceeding expectations by 5.21%. However, the stock saw a slight decline of 0.03% the following day, indicating mixed investor sentiment.
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+9.57%
Avg 1-day reaction
+4.27%
Analysts expect CRL to deliver solid earnings this quarter, with a consensus EPS of $2.74 and revenue of $977 million. The market is closely watching for any signs of growth or challenges in the life sciences sector.
Bull case
If CRL beats expectations, it could signal strong demand for its services, potentially leading to increased investor confidence and a positive stock reaction.
Bear case
Conversely, if the company misses its targets, it may raise concerns about market demand and operational challenges, leading to a negative impact on the stock.
Key metrics to watch
EPS
$2.74Earnings per share is a critical measure of profitability, indicating how much profit is allocated to each share of stock.
Revenue
$977MTotal revenue reflects the company's ability to generate sales and is a key indicator of business growth.
The print will turn on these.
Q1
Will CRL achieve an EPS of at least $2.74?
This specific EPS target is crucial as it reflects the company's profitability and can significantly influence investor sentiment.
Q2
What are the revenue figures for this quarter?
Revenue is a key indicator of business performance and growth, and any deviation from the consensus could impact future guidance.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The consensus may underestimate CRL's ability to capitalize on growing demand in the life sciences sector, particularly if they can showcase strong revenue growth this quarter.
Supporting evidence
The company has consistently beaten EPS estimates, indicating strong operational performance.
Options pricing suggests a higher expected move than historical averages, indicating market anticipation of significant news.
Key risk
If revenue comes in below $958 million, it could raise serious concerns about the company's growth trajectory.
Pre-commit to what would confirm each case.
The market is weighing the company's ability to maintain profitability and revenue growth amidst a competitive landscape.
Bull confirmed if
An EPS of $2.80 or higher would confirm strong operational performance and investor confidence.
Bear confirmed if
An EPS below $2.68 could signal potential issues in demand or operational challenges.
What the market is pricing for the move.
Implied Move
±10.01%
Historical Avg
±8.3%
The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.
Options are pricing ±10.0% while CRL has averaged ±8.3% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
60.1%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$2,974.30
10 sh
1 insider
Sold
$302,579.64
981 sh
1 insider
Net
$299,605.34
Net selling
Most Active Insiders· 2 open-market trades
$302,579.64
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
122.92%
of float
Insider
0.47%
of float
Holders
801
institutions
Top Holders· as of Jun 2026
FMR, LLC
4,239,752 sh · $1.3B
8.88%
22.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If CRL beats expectations, history suggests the stock could rise by an average of 1.27%, confirming strong demand and operational efficiency.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further commentary on future growth.
Miss
A miss could lead to a decline, with historical data suggesting an average drop of 0.03% following previous earnings surprises.
The lines on the call that would change the story.
$2,974.30
Net buying
Recent Transactions
Oct 5, 2026 · @ $308.44
981 sh
$302,579.64
Sep 30, 2026 · @ $297.43
10 sh
$2,974.30
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Blackrock Inc.
3,798,560 sh · $1.1B
7.96%
-1.6%
Vanguard Capital Management LLC
3,149,288 sh · $945.7M
6.60%
-1.7%
Invesco Ltd.
2,984,785 sh · $896.3M
6.25%
24.5%
Harris Associates L.P.
2,241,144 sh · $673.0M
4.69%
4.1%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.